iHealthScreen Accomplishments (Highlights)

- **Received European CE Certification, Australian Health approval, and Abu Dhabi Health approval** for Early Diagnosis of Diabetic Retinopathy (DR), Age-Related Macular Degeneration (AMD), and Glaucoma
- **AMD** FDA 510K is submitted with the completion of prospective trials. **Completed prospective trials for SR** and in the process of FDA 510K submission (final stage); Earlier, **Two FDA** pre-submission meetings validated the clinical study approach; Positive feedback on the final submission
- Awarded **$2.7M of NIH SBIR grants** on Stroke and Late AMD screening and prediction
- **Received one US Patent** for Predicting Late Age-related Macular Degeneration
- **Filed 3 non-provisional patent applications** for 4 disease predictions: i) stroke and heart attack prediction, ii) glaucoma detection, and iii) brain white matter lesion for Alzheimer's/Dementia prediction
- **Received insurance reimbursement approval** in Abu Dhabi (United Arab Emirates).
- **Signed a licensing agreement with iCare Inc.,** a top color fundus camera company with a $150M market cap.
- **Stroke and heart attack prediction models are validated against an external dataset** and are now ready for clinical trials (aim to submit an **FDA Class I application** by the end of February 2023; waiting for an NIH SBIR Phase II grant outcome of $2.2M)
- **An NDA was signed with Alexion** to start collaboration on the Late AMD prediction model (an active partnership discussion has been ongoing with **Roche**)
- **First prediction model for Late AMD (first US patent)**; featured work at ARVO 2018 (interviewed by Macular News); Featured at American Academy of Ophthalmology (AAO) 2020
- **AMD, DR, and Glaucoma results are published in the top journals and presented/featured at the ARVO, and Selected for Panel discussion at the American Academy of Ophthalmology (AAO) conference.**
- **Selected in the START-UP New York** Program (10 years tax-free (sales, procurement, and payroll taxes) in NY state and NY City)
- **Accepted by HUB71 program in Abu Dhabi,** a govt. funded prestigious acceleration program in Middle East with AED 500K support (equivalent to USD139K)
- **Customer segment determination/validation** is completed through a rigorous **NIH I-Corps** process (national program)
- **Developed two versions of EHR software with individual's health profiling:** iPredict is operational in US market; MyHealth is operational in Bangladesh. Both systems allow providers to: securely and instantly access patient information; create and customize notes; use voice dictation; provide video consultation; and create e-prescriptions. A telemedicine feature is also integrated with both systems.

- **A telemedicine App 'callMYDoctor'** is developed and available in iOS and Android app stores
- **Developed iPredict™**, an AI and telemedicine-based HIPPA-compliant software product for automated screening, prediction, and referral of individuals at risk of developing late-stage age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma.
- **Developed Retinal Pathology Progression Analyzer (RPPA),** which can analyze retinal pathology to find the progression of a person with Diabetic Retinopathy, Age-related Macular Degeneration (AMD), and other eye diseases.
- **Developed Retinal Vessel Analyzer (REVA),** which automatically analyzes retinal blood vessels to find the individual's risk for systemic diseases.
- **Completed NIH I-Corp National Program and ELab New York City Acceleration Program** (highly competitive programs)
- **Company has customers such as Burjeel (a top hospital chain in UAE with $B revenue, Bangladesh Diabetes Society). In the final stage of signing contracts with Mediclinic, and two other hospitals in UAE for DR, AMD, and glaucoma screening.**